Evolv Technologies Holdings, In
7.66-0.49 (-6.01%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · EVLV · USD
Key Stats
Market Cap
1.32BP/E (TTM)
-Basic EPS (TTM)
-0.55Dividend Yield
0%Recent Filings
8-K
Evolv boosts outlook, reports Q2 growth
Evolv Technologies reported Q2 2025 revenue of $32.5 million, up 29% year-over-year, with ARR hitting $110.5 million, a 27% rise, and positive Adjusted EBITDA of $2.0 million. The company raised its full-year revenue outlook to $132-$135 million, signaling 27%-30% growth amid strong customer wins exceeding 1,000 total. Chief Innovation Officer Michael Ellenbogen steps down September 5, 2025, due to time commitments, but stays on the board. Yet volatility in warrant liabilities drove a $40.5 million net loss.
10-Q
Q2 FY2025 results
Evolv Technologies Holdings, Inc. filed its 10-Q for the quarter ended June 30, 2025, but the document provided contains only the cover page and table of contents, with no financial statements, MD&A, or notes included. Without access to revenue, profitability, or balance sheet figures, key metrics like y/y or q/q deltas for revenue, EPS, cash flow, and debt cannot be analyzed or reported. Non-GAAP metrics are not disclosed in the 10-Q. Liquidity details, M&A activity, and risk factors remain unexamined due to missing content. Investors should await the complete filing for substantive insights. Competition in security technology poses ongoing challenges.
8-K
Evolv secures $75M credit facility
Evolv Technologies Holdings, Inc. entered into a $75 million senior secured credit facility with MidCap Financial Trust on July 29, 2025, featuring a $30 million initial term loan, a $30 million delayed draw term loan available over two years, and a $15 million revolving facility, all maturing in five years at SOFR plus 5.25%. Proceeds will fund general corporate purposes, bolstering liquidity amid rising demand for the company's subscription-based security solutions. The agreement imposes covenants on minimum annual recurring revenue, EBITDA starting in 2027, and liquidity tied to litigation resolution, while securing first liens on substantially all assets. This non-dilutive financing strengthens Evolv's balance sheet but ties flexibility to covenant compliance.
8-K
Registration amendment filed
Evolv Technologies filed a post-effective amendment to its shelf registration on July 1, 2025, switching from Form S-3 to S-1 after a restatement made the original ineffective under SEC rules. This procedural step registers resales of prior securities and warrant exercises without adding new shares. No fresh capital raise here. Filing ensures compliance amid the restatement's fallout.
8-K
Annual meeting results approved
Evolv Technologies Holdings held its annual stockholder meeting on June 20, 2025, with 72.41% of shares present. Shareholders elected Kevin Charlton, John Kedzierski, Kimberly Sheehy, and Bilal Zuberi as Class I directors until 2028. They also approved executive compensation on an advisory basis and ratified PricewaterhouseCoopers as auditors for 2025. Strong turnout signals investor alignment.
IPO
Website
Employees
Sector
Industry
BBAI
BigBear.ai, Inc.
6.90+0.12
BKYI
BIO-key International, Inc.
0.91-0.03
DTII
Defense Technologies Internatio
0.02-0.00
EVEX
Eve Holding, Inc.
4.56+0.17
EVH
Evolent Health, Inc
7.08-0.33
IVDA
Iveda Solutions, Inc.
1.33+0.04
LDDFF
Liberty Defense Holdings Ltd.
0.30-0.02
SUGP
SU Group Holdings Limited
6.65-0.32
WRAP
Wrap Technologies, Inc.
2.66+0.00
XTRAF
XTRACT ONE TECHNOLOGIES INC.
0.64+0.06